Hermes Vector

FDA

Every Hermes Vector story about FDA, newest first. Each one is checked against its sources.

What to know about FDA

The U.S. Food and Drug Administration (FDA) has issued a nationwide Class II recall for thousands of blood pressure medication bottles manufactured by Macleods Pharma USA due to failed dissolution specifications. Simultaneously, preliminary research presented at the American Heart Association's Scientific Sessions 2026 links caffeinated energy drinks and stimulant supplements to a significantly higher frequency of reported cardiac events.

Blood Pressure Medication Recall

On October 7, 2026, Macleods Pharma USA initiated a recall for certain lots of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Tablets. The FDA designated this as a Class II recall on October 26, 2026, noting that use may cause temporary or medically reversible adverse health consequences. The recall involves 3,744 bottles total: 3,528 30-count bottles from lot 12251163A and 216 90-count bottles from lot 12251163B, both expiring May 31, 2027. The medication failed quality standards because the pills did not dissolve as required during testing, which could affect how the body absorbs the active ingredients.

Energy Drink Safety Study

Preliminary research presented at the American Heart Association's Scientific Sessions 2026 analyzed 28,345 adverse-event reports submitted to the FDA between 2017 and 2025. The study found that cardiac arrest was reported approximately 11 times more often in connection with caffeine- and stimulant-containing products compared to products without those ingredients. Additionally, heart attacks were reported about 4.5 times more frequently, and ventricular arrhythmias or heart palpitations were reported four times more often. Approximately 45% of the reports linking these products to cardiovascular events involved adults between the ages of 18 and 34.

Research Limitations

Study author Sai Samayamanthula, a medical student at the University of Virginia School of Medicine, noted that the analysis design only identified associations within voluntarily self-reported data. Gregory M. Marcus, M.D., M.A.S., FAHA, who was not involved in the study, stated that the results do not prove that caffeine products cause these events because other factors may have influenced the results. Because the FDA regulates energy drinks and stimulant supplements as foods or dietary supplements rather than medications, these products do not undergo the same premarket safety testing required for medications.

Written with AI assistance from our source-checked stories below, and checked against them. Updated November 4, 2026.

More stories

Health

FDA rejects Summit Therapeutics' Ivonescimab cancer drug

The FDA rejected Summit Therapeutics' Ivonescimab, a cancer drug invented by Akeso and licensed to Summit in a deal worth up to $5bn, citing insufficient evidence of effectiveness and no significant survival benefit.

Checked against 4 sourcesft.commlq.aibriefs.co+1 more

HealthTrending

FDA requires NAION warning labels on all GLP-1 medications

The FDA is requiring all GLP-1 drugs, including Ozempic, Wegovy, Mounjaro and Zepbound, to carry a warning about a rare eye condition that can cause permanent vision loss.

Checked against 6 sourcesThe Guardianinkl.comcbsnews.com+3 more
Loading more stories…